Literature DB >> 12769609

Targeting neuronal nicotinic receptors: a path to new therapies.

Merouane Bencherif1, Jeffrey D Schmitt.   

Abstract

The structural heterogeneity, the ubiquity of anatomical distribution, and the demonstrated modulation of biological functions is consistent with the view that nicotinic cholinergic signaling plays a key regulatory role in the brain and influences a number of neuronal processes including sensory processing, motor activity, and cognitive function. It has become evident that perturbation of nicotinic cholinergic neurotransmission can result in diverse CNS pathologies providing the potential for therapeutic intervention in a number of neurodegenerative, neuropsychiatric and neurological disorders. This review will provide a status on the rationale for neuronal therapies targeting neuronal nicotinic receptors (nAChRs) and discusses the multifaceted beneficial effects than can be achieved through manipulation of cholinergic pharmacology. Recent advances and issues relating to rational drug design based on the structure of acetylcholine binding protein are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12769609     DOI: 10.2174/1568007023339094

Source DB:  PubMed          Journal:  Curr Drug Targets CNS Neurol Disord        ISSN: 1568-007X


  7 in total

1.  Identification of N-terminal extracellular domain determinants in nicotinic acetylcholine receptor (nAChR) α6 subunits that influence effects of wild-type or mutant β3 subunits on function of α6β2*- or α6β4*-nAChR.

Authors:  Bhagirathi Dash; Minoti Bhakta; Yongchang Chang; Ronald J Lukas
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

2.  Protonation-induced stereoisomerism in nicotine: conformational studies using classical (AMBER) and ab initio (Car-Parrinello) molecular dynamics.

Authors:  Philip S Hammond; Yudong Wu; Rebecca Harris; Todd J Minehardt; Roberto Car; Jeffrey D Schmitt
Journal:  J Comput Aided Mol Des       Date:  2005-01       Impact factor: 3.686

3.  Therapeutic potential of novel selective drugs targeting nicotinic acetylcholine receptors.

Authors:  Merouane Bencherif; Terry A Hauser; Kristen G Jordan; Gregory J Gatto
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

4.  Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.

Authors:  Joo-Cheol Shim; Do-Un Jung; Sung-Soo Jung; Young-Soo Seo; Deuk-Man Cho; Ji-Heon Lee; Sae-Woom Lee; Bo-Geum Kong; Je-Wook Kang; Min-Kyung Oh; Sang-Duk Kim; Robert P McMahon; Deanna L Kelly
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

Review 5.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

6.  Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors.

Authors:  Vladimir P Grinevich; Roger L Papke; Patrick M Lippiello; Merouane Bencherif
Journal:  Neuropharmacology       Date:  2009-05-28       Impact factor: 5.250

7.  Influence of acute or chronic calcium channel antagonists on the acquisition and consolidation of memory and nicotine-induced cognitive effects in mice.

Authors:  Grazyna Biala; Marta Kruk-Slomka; Krzysztof Jozwiak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-12       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.